[go: up one dir, main page]

WO2018134540A8 - Utilisation du récepteur-cd71 dans le pronostic et le traitement de l'endométriose - Google Patents

Utilisation du récepteur-cd71 dans le pronostic et le traitement de l'endométriose Download PDF

Info

Publication number
WO2018134540A8
WO2018134540A8 PCT/FR2018/050140 FR2018050140W WO2018134540A8 WO 2018134540 A8 WO2018134540 A8 WO 2018134540A8 FR 2018050140 W FR2018050140 W FR 2018050140W WO 2018134540 A8 WO2018134540 A8 WO 2018134540A8
Authority
WO
WIPO (PCT)
Prior art keywords
endometriosis
prognosis
receptor
treatment
targeting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2018/050140
Other languages
English (en)
Other versions
WO2018134540A1 (fr
Inventor
Pierre Launay
Coralie BELANGER
Cécile Real
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ENDODIAG
Inatherys
Original Assignee
ENDODIAG
Inatherys
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ENDODIAG, Inatherys filed Critical ENDODIAG
Priority to US16/478,979 priority Critical patent/US20190352415A1/en
Priority to JP2019539949A priority patent/JP2020505389A/ja
Priority to EP18704276.7A priority patent/EP3571220A1/fr
Publication of WO2018134540A1 publication Critical patent/WO2018134540A1/fr
Anticipated expiration legal-status Critical
Publication of WO2018134540A8 publication Critical patent/WO2018134540A8/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70582—CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70582—CD71
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention a pour objet l'utilisation du récepteur CD71 comme cible dans le pronostic et/ou le traitement de l'endométriose ainsi qu'un test de pronostic ou de suivi thérapeutique de l'endométriose, ciblant ce récepteur.
PCT/FR2018/050140 2017-01-20 2018-01-19 Utilisation du récepteur-cd71 dans le pronostic et le traitement de l'endométriose Ceased WO2018134540A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US16/478,979 US20190352415A1 (en) 2017-01-20 2018-01-19 Use of the cd71 receptor in the prognosis and treatment of endometriosis
JP2019539949A JP2020505389A (ja) 2017-01-20 2018-01-19 子宮内膜症の予後及び治療におけるｃｄ７１受容体の使用
EP18704276.7A EP3571220A1 (fr) 2017-01-20 2018-01-19 Utilisation du récepteur-cd71 dans le pronostic et le traitement de l'endométriose

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1750468A FR3062213B1 (fr) 2017-01-20 2017-01-20 Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose
FR17/50468 2017-01-20

Publications (2)

Publication Number Publication Date
WO2018134540A1 WO2018134540A1 (fr) 2018-07-26
WO2018134540A8 true WO2018134540A8 (fr) 2019-08-29

Family

ID=59409385

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2018/050140 Ceased WO2018134540A1 (fr) 2017-01-20 2018-01-19 Utilisation du récepteur-cd71 dans le pronostic et le traitement de l'endométriose

Country Status (5)

Country Link
US (1) US20190352415A1 (fr)
EP (1) EP3571220A1 (fr)
JP (1) JP2020505389A (fr)
FR (1) FR3062213B1 (fr)
WO (1) WO2018134540A1 (fr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR703601A0 (en) * 2001-08-15 2001-09-06 Peter Maccallum Cancer Institute, The Identification and isolation of somatic stem cells and uses thereof
EP2332995A1 (fr) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralisation d'anticorps récepteurs de prolactine et leur utilisation thérapeutique
FR2953841B1 (fr) * 2009-12-16 2011-12-30 Centre Nat Rech Scient Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer
FR2979530B1 (fr) 2011-09-05 2013-09-27 Endodiag Dispositif pour le prelevement laparoscopique d'un echantillon cylindrique superficiel d'un tissu du corps humain ou animal
AU2013203422A1 (en) * 2012-01-06 2013-07-18 Bioalliance C.V. Anti-transferrin receptor antibodies and methods using same
US10969391B2 (en) * 2014-07-11 2021-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing hematological cancers
HUE057720T2 (hu) * 2015-05-04 2022-06-28 Cytomx Therapeutics Inc Aktiválható anti-CD71 antitestek és ezek alkalmazási eljárásai
KR102690998B1 (ko) 2015-07-22 2024-07-31 이나터리 항-TfR 항체 및 증식성 및 염증성 장애의 치료에서의 그의 용도
WO2017132230A1 (fr) * 2016-01-25 2017-08-03 Novozymes A/S Procédé pour réduire la prolifération microbienne dans un couvoir à volailles

Also Published As

Publication number Publication date
FR3062213A1 (fr) 2018-07-27
WO2018134540A1 (fr) 2018-07-26
EP3571220A1 (fr) 2019-11-27
US20190352415A1 (en) 2019-11-21
JP2020505389A (ja) 2020-02-20
FR3062213B1 (fr) 2021-02-26

Similar Documents

Publication Publication Date Title
PH12018500086A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
PH12017501077A1 (en) Compositions and methods for antibodies targeting bmp6
EP4378536A3 (fr) Inhibiteurs peptidiques oraux du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies intestinales inflammatoires
MX384192B (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
MY193723A (en) Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
MX2017006217A (es) Polinucleotidos moduladores.
MX356107B (es) Histidil-arnt sintetasas para tratar enfermedades autoinmunes e inflamatorias.
EP3486256A3 (fr) Anticorps et fragments de liaison à l'antigène qui se lient spécifiquement à la protéine tau associée aux microtubules
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
CA3174958C (fr) Anticorps contre l’inhibiteur de la voie du facteur tissulaire
EP3705494A3 (fr) Anticorps contre les protéines frizzled et leurs méthodes d'utilisation
CA3073829A1 (fr) Methodes et compositions de detection et de traitement de l'endometriose
EP4417262A3 (fr) Polythérapie
EP4603508A3 (fr) Anticorps anti-fzd et méthodes d'utilisation
MX2018012493A (es) Métodos para controlar y tratar el cáncer.
PH12017501990B1 (en) Imidazopyrazinones as pde1 inhibitors
EP3164125B8 (fr) Méthodes et compositions permettant de traiter l'obésité, prévenir la prise de poids, favoriser la perte pondérale, favoriser l'amincissement, et traiter ou prévenir le développement du diabète
PH12019502694A1 (en) Anti-trkb antibodies
HK1249431A1 (zh) 修饰的酵母-短尾畸形(brachyury)免疫治疗组合物
EP4331622A3 (fr) Peptides de liaison à l'intégrine et leurs utilisations
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
PH12016501495A1 (en) Hexahydrofuropyrroles as pde1 inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18704276

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019539949

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018704276

Country of ref document: EP

Effective date: 20190820